We finally established using immunofluorescence studies with anti-CD68, anti-arginase and anti-CD206 that the combined treatment leads to the activation of TAMs with an M1 phenotype directly into the tumor spheroids whereas TAMs express an M2-like phenotype without treatment. The gene discussed is MRC1; the disease is neoplasm.